105P CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, locally advanced breast cancer (LABC): Biological and clinical activity, and post-surgical approaches
Sara Parola, C. De Angelis(Federico II University Hospital), Pietro De Placido(University of Naples Federico II), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Grazia Arpino(University of Naples Federico II), Vincenzo Di Lauro(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Valeria Forestieri(University of Naples Federico II), Mario Giuliano(Regione Campania), Daniela Cianniello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Claudia von Arx(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Sabino De Placido, Rossella Lauria, Erica Pietroluongo(Federico II University Hospital), Martina Pagliuca(Scuola Superiore Meridionale), R. Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppe Buono(Federico II University Hospital)
Cited by 1
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413